CID 2011756 is an ATP competitive PKD inhibitor, with an IC50 of 3.2 μM for PKD1 in cell free assay, and also shows cellular pan-PKD inhibitory activity against PKD2 and PKD3 (IC50, 0.6 and 0.7 μM, respectively). CID 2011756 also has antitumor activity.
性状
Solid
IC50 & Target[1][2]
Cellular PKD2
0.6 μM (IC50)
Cellular PKD3
0.7 μM (IC50)
PKD1
3.2 μM (IC50)
体外研究(In Vitro)
CID 2011756 is an ATP-competitive PKD1 inhibitor, with an IC50 of 3.2 μM. CID 2011756 decreases the phosphorylation of endogenous PKD1 Ser in LNCaP cancer cells with an EC50 of 10±0.7 μM. CID 2011756 also has cellular pan-PKD inhibitory effects, with IC50s of 0.6±0.1 μM and 0.7±0.2 μM for PKD2 and PKD3, respectively.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.